statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance  3L

Nationally Established Q Code Will Further Support the Use of Biovance 3L by Physicians to Treat Wound Care Patients in Office SettingsFLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE...

Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc. (NASDAQ: CELU) breached...

Celularity submits request to FDA for orphan drug designation for PDA-002

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Company Has Already Received IND Clearance from the FDA and Plans to Begin Phase 1/2 Study in 2024 with Off-the-Shelf, Placental-Derived Cell TherapyFLORHAM PARK, N.J., March 20, 2024 (GLOBE...

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Presentation Will Discuss Cellular Immunotherapy's Potential Role in Treating Chronic Conditions and Extending People's LivesFLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc...

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's DiseaseFLORHAM PARK, N.J., March 12, 2024 (GLOBE...

Celularity to present in vivo data from T-cell therapy platform at AACR

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024FLORHAM PARK, N.J...

Celularity trading halted, news pending

Celularity Stock to Reverse Split on Thursday, February 29th (NASDAQ:CELU)

Celularity Inc. (NASDAQ:CELU  Free Report)s stock is going to reverse split before the market opens on Thursday, February 29th. The 1-10 reverse split was announced on Thursday...

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Volume	7,744.00
52-Wk High	$7.97
52-Wk Low	$1.59

CELU Celularity Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals